Citation Impact
Citing Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
2005 Standout
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
2005 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
1999
5 Treatment and prognostic factors in acute myeloid leukaemia
1996
Targeting cancer metabolism: a therapeutic window opens
2011
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: A review
2013
Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration
1995 StandoutNobel
“Pulse” Nasal Mupirocin Maintenance Regimen in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis
1999
Association of a Leukemic Stem Cell Gene Expression Signature With Clinical Outcomes in Acute Myeloid Leukemia
2010
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
2016
Cytogenetics in acute leukemia
2003
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
2005
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Diagnosis and management of refractoriness to platelet transfusion
2001
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Acute Lymphoblastic Leukemia
1998
Clinicopathological features of acute undifferentiated leukaemia with a stem cell phenotype
1990
Clinical applications of quinone-containing alkylating agents
2000
The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia
2004
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
2008 Standout
Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222
2004
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
DT-diaphorase and cancer chemotherapy
1992
The HIV-associated tuberculosis epidemic—when will we act?
2010
Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial
2007
Chronic Renal Failure after Transplantation of a Nonrenal Organ
2003 Standout
Cytogenetics and their prognostic value in de novo acute myeloid leukaemia: a report on 283 cases
1989
Clinical Pharmacokinetics of Ibuprofen
1998
Targeting multidrug resistance in cancer
2006 Standout
A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31
2001
Salvage Therapy for Refractory or Relapsed Acute Lymphocytic Leukemia
2001
Persistent (not intermittent) nasal carriage ofStaphylococcus aureus is the determinant of CPD-related infections
2005
Tuberculosis control and elimination 2010–50: cure, care, and social development
2010 Standout
Gout
2016 Standout
Clinical Pharmacokinetics of Tacrolimus
1995 Standout
Nonsteroidal Antiinflammatory Drugs — Differences and Similarities
1991
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa
2006 Standout
Expresssion of a 95 kDa membrane protein is associated with low daunorubicin accumulation in leukaemic blast cells
1995
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Resistance to oxidants associated with elevated catalase activity in HL-60 leukemia cells that overexpress multidrug-resistance protein does not contribute to the resistance to daunorubicin manifested by these cells
1995
Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
2001 Standout
ACUTE MYELOID LEUKAEMIA IN THE ELDERLY: BIOLOGY AND TREATMENT
1993
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
2013 Standout
Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs
1992
Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment
2006
The role of nasal carriage in Staphylococcus aureus infections
2005 Standout
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse
1995 StandoutNobel
Role of Formulation Vehicles in Taxane Pharmacology
2001
Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors
1994
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
2010 Standout
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
2002
Treatment of Acute Lymphoblastic Leukaemia
2007
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.
1997
Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO)
1991
A Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous Leukemia
1995
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Opportunities and Challenges for HIV Care in Overlapping HIV and TB Epidemics
2008
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study
2006
The prognostic landscape of genes and infiltrating immune cells across human cancers
2015 Standout
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
2009 Standout
Chronic Kidney Disease
2016 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Allopurinol Hypersensitivity: A Systematic Review of All Published Cases, 1950–2012
2013
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Overview of Platelet Transfusion
2010
Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML
1992
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
The Activation of Carboxylic Acids via Self-Assembly Asymmetric Organocatalysis: A Combined Experimental and Computational Investigation
2016 StandoutNobel
Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)
1997
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
1999 StandoutScience
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
2001
Tumour stem cells and drug resistance
2005 Standout
Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420
1999
Leukocyte lipid body formation and eicosanoid generation: cyclooxygenase-independent inhibition by aspirin.
1996 StandoutNobel
Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources.
2006
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
2003 Standout
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
2002
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621
2004
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
2001
Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022
1997
Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.
1996
Active case finding of tuberculosis: historical perspective and future prospects.
2005
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
Posttransplantation Diabetes
2002
Leukocyte Reduction and Ultraviolet B Irradiation of Platelets to Prevent Alloimmunization and Refractoriness to Platelet Transfusions
1997
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study
1997
Adult Patients With De Novo Acute Myeloid Leukemia and t(9; 11)(p22; q23) Have a Superior Outcome to Patients With Other Translocations Involving Band 11q23: A Cancer and Leukemia Group B Study
1997
Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
2001
Platelet Transfusion for Patients With Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
2001
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered
1999
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features
1996 Standout
Reversal of anticancer multidrug resistance by the ardeemins
1998
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
1997
Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
1998
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
1997
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
1998
A randomized placebo-controlled phase III study of granulocyte- macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)
1995
Declines in Lung Function After Antiretroviral Therapy Initiation in Adults With Human Immunodeficiency Virus and Tuberculosis: A Potential Manifestation of Respiratory Immune Reconstitution Inflammatory Syndrome
2019 StandoutNobel
K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients
2005
The biology and treatment of acute lymphoblastic leukemia in adults
1995
A multidrug resistance transporter from human MCF-7 breast cancer cells
1998 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells
2010 StandoutNobel
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
2004
Intranasal Mupirocin does not Prevent Exit-Site Infections in Children Receiving Peritoneal Dialysis
2003
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
1998 Standout
Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia
1995
Pharmacological and clinical evaluation of l-asparaginase in the treatment of leukemia
2006
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
1999 StandoutScience
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
2009 Standout
Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase 1 gene
1996 Standout
Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression
1993
Equipotent inhibition by R(−)−, S(+)‐ and racemic ibuprofen of human polymorphonuclear cell function in vitro.
1993
Allopurinol Hypersensitivity Syndrome: A Review
1993
Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
1997
Works of EJ Lee being referenced
An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group B
1998
Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana
2003
High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients
1984
Lipoprotein (a) levels and clinical correlations in CAPD patients.
1995
Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine.
1991
Minimally differentiated acute nonlymphocytic leukemia: a distinct entity
1987
Clinical evaluation of platelet concentrates stored for one to five days
1986
Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets
1989
Acinetobacter peritonitis in patients on CAPD: characteristics and outcome.
1991
Selection of histocompatible apheresis platelet donors by cross- matching random donor platelet concentrates
1992
Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL
1994
Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia
1989
The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients
1996
Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia
1993
Posttransplant diabetes mellitus after renal transplantation in Korea.
1996
Allopurinol--induced skin reactions and agranulocytosis.
1982
Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia
1986
Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients
1987
Stereoselective disposition of ibuprofen enantiomers in man.
1985
Staphylococcus aureus CAPD-related infections are associated with nasal carriage.
1994
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811
1995
High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients
1984
Minimally differentiated acute nonlymphocytic leukemia: a distinct entity
1987